China NMPA Drug Inspection - Dijia Pharmaceutical Group Co., Ltd - Norfloxacin capsules

China NMPA drug inspection for Dijia Pharmaceutical Group Co., Ltd published June 01, 2016. Drug: Norfloxacin capsules.

One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.

Record Summary

China NMPA drug inspection for Dijia Pharmaceutical Group Co., Ltd published June 01, 2016. Drug: Norfloxacin capsules.

Get More Insights

Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.

1.5M+ regulatory data points

Real-time compliance monitoring

Interactive analytics dashboard

Looking for more records? Our platform provides access to thousands of similar regulatory documents with advanced search and filtering capabilities.

Record Information

Company

Dijia Pharmaceutical Group Co., Ltd

Inspection Date

Unknown Date

Product Type

ID: 7c860340-1f74-4aaf-9c4f-71fdffa5b797

View on Dashboard

Transform Regulatory Data into Actionable Intelligence

Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.

Try KeyPedia Today

Explore our real use cases and discover our features in depth.

Subscribe to our newsletter

Get the latest updates and insights delivered to your inbox